Revolution Medicines (RVMD) Income from Continuing Operations (2019 - 2026)

Revolution Medicines has reported Income from Continuing Operations for 8 years, with the latest figure at -$644.4 million in Q2 2026.

• On a quarterly basis, Income from Continuing Operations fell 160.05% year-over-year to -$644.4 million in Q2 2026; TTM through Jun 2026 was -$1.8 billion, a 117.77% decrease from a year earlier, with the FY2025 full-year figure at -$893.7 million, down 48.94% from the prior year.
• Income from Continuing Operations was -$644.4 million for Q2 2026 at Revolution Medicines, down from -$453.8 million in the prior quarter.
• The five-year high for Income from Continuing Operations was -$56.5 million in Q4 2022, with the low at -$644.4 million in Q2 2026.
• Average Income from Continuing Operations over 5 years is -$195.3 million, with a median of -$144.8 million recorded in 2024.
• The sharpest annual moves came in 2022 and 2023: Income from Continuing Operations slipped 7.27% in 2022, then plunged 187.27% in 2023.
• Over 5 years, Income from Continuing Operations stood at -$56.5 million in 2022, then sank by 187.27% to -$162.3 million in 2023, then decreased by 19.83% to -$194.5 million in 2024, then plunged by 87.58% to -$364.9 million in 2025, then tumbled by 76.59% to -$644.4 million in 2026.
• The last three Income from Continuing Operations figures came in at -$644.4 million (Q2 2026), -$453.8 million (Q1 2026), and -$364.9 million (Q4 2025), per Business Quant data.